On September 8, 2026 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the "Company"), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, reported it will participate in two investor conferences during September.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
H.C. Wainwright 28th Annual Global Investment Conference, September 14-16 at the Lotte New York Palace Hotel. Management will hold one-on-one meetings with investors during the conference. A virtual presentation will be available on demand here starting Friday, September 11th at 7:00 a.m. Eastern time.
ROTH Capital 5th Annual Healthcare Opportunities Conference, September 29 at The Metropolitan Club in New York City. Management will participate in a panel titled "Frontiers in Neuroscience" at 10:00 a.m. Eastern time. In addition, management will hold one-on-one and small group meetings with investors.
Dr. Iwaki comments, "These conferences underscore our commitment to regular interaction and communication with all stakeholders connected to our progress. We continue to work diligently toward an announcement around our key milestones. We expect to report topline data from our Phase 2 MN-001-NATG-202 study in metabolic disease by end of Q3, followed by a topline readout from the double-blind phase of our lead program, the COMBAT-ALS study of MN-166 by year-end. In the meantime, we continue to carefully manage our $25.4 million cash position as of Q2 2026 to ensure sufficient capital to execute on our business and demonstrate optimal shareholder value. We look forward to speaking with investors at each of these conferences, and at subsequent opportunities."
(Press release, MediciNova, SEP 8, 2026, View Source [SID1234670631])